Shares of GeoVax Labs (GOVX) traded as high as $6.19 with more than 11.4M shares exchanging hands at 11:00 am EST. GeoVax Labs Inc seems to be in the right spot at the right time – “Vaccine” for COVID-19.
GOVX is working on a single-dose COVID vaccine that requires no refrigeration. It looks like the company is currently working on pre clinical animal studies and could move into the clinic for testing very soon. The news with NIH is more compelling to Wall Street. GOVX has signed two additional license agreements with the NIH allowing the use of patent rights and licensed materials in combination with its proprietary technology to develop, manufacture and commercialize a preventive vaccine against COVID-19.
With the National Institutes of Health (NIH) asking for more vaccine proposals, GeoVax says it’s poised to make new submissions.
GOVX is also turning heads in the HIV sector. The company has synthesized a preventive HIV vaccine candidate to fight against the subtype of HIV prevalent in the commercial markets of the Americas, western Europe, Japan and Australia.